If you liked this article you might like

Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo
Cramer's 'Mad Money' Recap (Tuesday 1/3/17): Better Buying Opportunities Are Lurking
Cramer: Reviewing S&P's Hit-and-Miss Parade
3 Troubled Companies and How to Play Them in the New Year